ONCT Oncternal Therapeutics
- 8.1790
- -0.4560-5.28%
Oncternal Therapeutics News
Oncternal Therapeutics | 10-Q: Quarterly report
Oncternal Therapeutics Q1 2024 GAAP EPS $(2.83) Beats $(2.88) Estimate, Sales $569.000K Beat $176.667K Estimate
Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(2.83) per share which beat the analyst consensus estimate of $(2.88) by 1.74 percent. This is a 27.99 percent increase over losses o
Oncternal Therapeutics 1Q Loss/Shr $2.83 >ONCT
Oncternal Therapeutics 1Q Loss/Shr $2.83 >ONCT
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today anno
Oncternal Announces First Patient Dosed In Fourth Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in
Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Oncternal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : Oncemic Therapeutics (ONCT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $30.00 to $28.00.
HC Wainwright & Co. : Oncemic Therapeutics (ONCT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $30.00 to $28.00.
HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $28
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oncternal Therapeutics with a Buy and lowers the price target from $30 to $28.
Oncternal Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 197.87% HC Wainwright & Co. $30 → $28 Maintains Buy 01/29/2024 219.15% HC Wainwright & Co. $2 →
AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
IRVINE, Calif., April 11, 2024 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chief executive officer Hans Keirstea
Oncternal Therapeutics(ONCT.US) Director Buys US$27,654.57 in Common Stock
$Oncternal Therapeutics(ONCT.US)$ Director Wills Robert James purchased 3,086 shares of common stock on Apr 8, 2024 at an average price of $8.9613 for a total value of $27,654.57.Source: Announcement
Insiders Buying Westlake Chemical Partners And 2 Other Stocks
Although U.S. stocks closed mostly lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view t
Oncternal Therapeutics(ONCT.US) Director Buys US$58,602.37 in Common Stock
$Oncternal Therapeutics(ONCT.US)$ Director Wills Robert James purchased 6,914 shares of Common Stock on Mar 28, 2024 at an average price of $8.4759 for a total value of $58,602.37.Source: Announcement
Oncternal Participating in Virtual Fireside Chat With Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will
Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
Oncternal Therapeutics Files for Mixed Shelf Offering
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Q4 2023 Oncternal Therapeutics Inc Earnings Call
Analysis
Price Target
No Data
